Pharmaceuticals, Biotechnology and Life Sciences
Revenue at September 30, 2025 Return to growth in Q3 2025 9-month revenue: €586.5 million, down 2.8% at CER1 and…
Secarna to collaborate with Scenic to develop first-in-class disease-modifying oligonucleotide therapies for severe genetic diseases.
— First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related…
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of…
• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company’s Board of Directors…
FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it…
GERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) — Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on…
MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly…
VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction…
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces…